自体干细胞移植治疗POEMS综合征的肺部并发症
Pulmonary morbidity improves after autologous stem cell transplantation in POEMS syndrome
Satish Chandrashekaran, M.B.B.S.1e, Angela Dispenzieri, M.D.e, Stephen S. Cha, M.P.H.e, Cassie C. Kennedy, M.D.e
1Present address: Division of Pulmonary, Critical Care and Sleep Medicine, 1600 SW Archer Road, M451B, PO Box 100225, Gainesville, FL 32610, USA.
Background
POEMS syndrome is a plasma cell disorder manifested by Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes. Pulmonary morbidity includes restriction, decreased diffusing capacity for carbon monoxide (DLCO), respiratory muscle weakness, abnormal imaging, and pulmonary hypertension. Autologous peripheral blood stem cell transplantation (aPBSCT) is an effective treatment for POEMS syndrome. It is unknown if aPBSCT improves pulmonary morbidity. We hypothesize pulmonary morbidity will improve following aPBSCT.
Methods
Retrospective cohort study of POEMS syndrome aPBSCT recipients from 2000 to 2010. Demographic, pulmonary function test (PFT), echocardiogram, cytokine, and imaging data at baseline and after aPBSCT were ed. Pre- and post-transplant data were compared using Wilcoxon signed-rank and McNemar's tests.
Results
53 patients met criteria. Median improvements in forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and total lung capacity (TLC) after transplant were 180, 315 and 350 ml respectively (median follow-up of 1.1 years). DLCO, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) improved by a median of 11, 12.5 and 10% predicted respectively. RVSP and chest imaging also improved. Vascular endothelial growth factor and IL-6 decreased by a median of 334 and 2 pg/ml respectively. All comparisons were statistically significant. Longitudinal data demonstrated stability in FEV1, MEP, and TLC and continued improvement in FVC, MIP and DLCO on subsequent PFTs (median follow-up 26.5 months).
Conclusion
Patients with POEMS syndrome treated with aPBSCT have significant improvement in PFTs, respiratory muscle strength, imaging, and post-transplant IL-6. The improvement in PFTs persists during long-term follow-up.
respiratory medicine
January 2015Volume 109, Issue 1, Pages 122–130
DOI: http://dx.doi.org/10.1016/j.rmed.2014.11.005 |
copyright©金宝搏网站登录技巧 版权所有,未经许可不得复制、转载或镜像
京ICP证120392号 京公网安备110105007198 京ICP备10215607号-1 (京)网药械信息备字(2022)第00160号